Replimune (REPL) Q1 Loss Widens 61%
Replimune Group (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapies for cancer, reported its earnings for the first quarter of fiscal 2026 on August 7, 2025. The most notable headline was the U.S. Food and Drug Administration’s Complete Response Letter, issued on July 22, 2025, regarding approval of its RP1 therapy for advanced melanoma, which postponed the anticipated product launch and revenue generation. Net loss (GAAP) was $86.7 million. Actual GAAP earnings per share came in at $(0.95). The company reported no revenue in the quarter. Overall, the period marked a setback on the regulatory front, increased investment in both research and commercial infrastructure, and a higher cash burn rate than in previous periods.
Source: Analyst estimates for the quarter provided by FactSet.
Replimune Group is focused on developing immunotherapies using oncolytic viruses—engineered viruses that target and kill cancer cells while stimulating a patient’s immune response. Its lead product candidate, RP1, is being studied in combination with approved immunotherapies for melanoma and other cancers. The company's portfolio also includes RP2 and RP3, which is in earlier clinical trials targeting a range of solid tumors.
Source Fool.com
